Study
Exploring a tolerable and effective dosage of omega-3 fatty acids as a supplement in enterally fed patients with severe pneumonia: A pilot study.
A 7-day pilot in 84 severe-pneumonia patients found omega-3 doses were tolerated and linked to shorter ventilation.
Summary Can high-dose omega-3 help people with severe pneumonia recover faster? Show / hide ↓
Researchers randomly assigned 84 people with severe pneumonia who were receiving food through a feeding tube to three groups. For seven days, two groups received 3.50 or 8.75 grams of omega-3 fats daily, while the third received usual care. The researchers reported shorter time on mechanical ventilation, meaning a breathing machine, and lower hospital costs among those taking omega-3. Both doses were generally tolerated, but the study did not clearly show which dose worked better or provide enough detail to judge the size of the benefit.
What this means for you: This does not show that healthy people should buy high-dose omega-3 supplements. It was a small, short pilot study in very sick hospital patients, so the finding needs confirmation before guiding routine treatment.
early evidenceThis pilot study sought a tolerable omega-3 dose for enterally fed patients with severe community-acquired pneumonia. Eighty-four patients were randomly assigned to a control group or experimental groups receiving 3.50 g or 8.75 g/day of EPA plus DHA for seven days. The abstract reports that omega-3 supplementation significantly reduced mechanical-ventilation duration, hospital expenses and daily hospital costs. It does not provide the group sizes, effect estimates, p-values, or a comparison between the two omega-3 doses. The anticipated anti-inflammatory effect was not observed; instead, the authors describe a trend toward immune enhancement. Both active doses were relatively well tolerated. Mechanical-ventilation duration is a clinical outcome, but this short intervention was delivered to severely ill patients in intensive medical care, not healthy adults taking a routine supplement. The reported result therefore has limited relevance to prevention or longevity. The study was explicitly labelled a pilot, and the authors call for a larger, adequately powered trial to confirm benefits and establish the optimal dose. Until then, the evidence is suggestive rather than a settled basis for clinical use.
Omega-3 fatty acids at 3.50-8.75 g/day were relatively well tolerated and were associated with shorter mechanical-ventilation duration and lower hospital cost in this pilot study.
This was a seven-day pilot in patients with severe pneumonia, and the abstract omits effect sizes and group-specific results. The expected anti-inflammatory effect was not observed, and confirmation in a larger trial is needed.
Cited by
1 encyclopedia entries reference this study.